Previous Close | 0.1500 |
Open | 0.1500 |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 250.00 |
Expire Date | 2024-05-17 |
Day's Range | 0.1500 - 0.1500 |
Contract Range | N/A |
Volume | |
Open Interest | N/A |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
10x Genomics, Cardinal Health, Hologic, Boston Scientific and LabCorp are included in this Analyst Blog.
Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the U.S. Food and Drug Administration (FDA) has approved its nAbCyte™ Anti-AAVRh74var HB-FE Assay, a companion diagnostic (CDx) to determine patient eligibility for treatment with BEQVEZ™ (fidanacogene elaparvovec-dzkt), Pfizer's recently FDA-approved hemophilia B gene therapy.